Jianfei Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jianfei Luo has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Bing Qu
Department of Gastrointestinal Surgery, Renmin hospital of Wuhan University
3 shared publications- Bing Qu
Department of General Surgery, Renmin Hospital of Wuhan University, Wuhan, China
3 shared publications - Christopher Birigwa
Department of Gastrointestinal Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China
3 shared publications - Qiang Tong
Department of Gastrointestinal Surgery I Section, Renmin Hospital of Wuhan University, China
3 shared publications Jianguo Wu
Department of General Surgery Renmin Hospital of Wuhan University Wuhan Hubei China
2 shared publicationsJiasheng Liu
Department of General Surgery Renmin Hospital of Wuhan University Wuhan Hubei China
2 shared publications
Latest Publications
- 26 October 2026
- Published by Springer Nature in Current Medical Science
- p. 1-16
Ambient Air Pollution and Gastric Cancer Incidence: A Multinational Ecological Analysis (1990–2020)
Objective While ambient air pollution constitutes a major global health risk, its long-term association with gastric cancer burden at a global scale, especially its impact on vulnerable populations, remains poorly characterized. We examined the association between long-term exposure to ambient air pollution and gastric cancer incidence. Methods In this ecological study, we analyzed data from 204 countries (1990–2020) from the Global Burden of Disease 2021 study. We examined the association between age-standardized incidence rates of gastric cancer and long-term exposure to fine particulate matter (PM2.5), nitrogen dioxide (NO₂), and ozone (O₃). We used adjusted negative binomial fixed-effects panel regression, natural cubic splines for nonlinearity, stratified analyses by sex, age, and sociodemographic index (SDI), and lag models. Results Significant positive associations were found. Each one-unit increase in PM2.5, NO₂, and O₃ was associated with 0.3% (95% CI: 0.1–0.5%), 1.8% (1.2–2.4%), and 0.6% (0.3–0.9%) increases in overall incidence, respectively, at the population level. The exposure‒response relationships were nonlinear, with critical lag windows of 3–4 years for PM2.5 and 3 years for O₃. Stratified analyses revealed greater male susceptibility to PM2.5, whereas females were more vulnerable to NO₂ and O₃. High-middle-SDI regions had the highest PM2.5 risk, whereas low-middle-SDI regions were most affected by NO₂ and O₃. Adults aged ≥70 years face the highest risk, with females showing elevated susceptibility after age 60. Conclusion These ecological findings highlight the importance of considering air pollution in gastric cancer prevention frameworks, although the results must be validated by individual-level studies across diverse settings before causal inferences can be drawn.
- 26 October 2026
- Published by Springer Nature in Current Medical Science
- p. 1-16
Ambient Air Pollution and Gastric Cancer Incidence: A Multinational Ecological Analysis (1990–2020)
Objective While ambient air pollution constitutes a major global health risk, its long-term association with gastric cancer burden at a global scale, especially its impact on vulnerable populations, remains poorly characterized. We examined the association between long-term exposure to ambient air pollution and gastric cancer incidence. Methods In this ecological study, we analyzed data from 204 countries (1990–2020) from the Global Burden of Disease 2021 study. We examined the association between age-standardized incidence rates of gastric cancer and long-term exposure to fine particulate matter (PM2.5), nitrogen dioxide (NO₂), and ozone (O₃). We used adjusted negative binomial fixed-effects panel regression, natural cubic splines for nonlinearity, stratified analyses by sex, age, and sociodemographic index (SDI), and lag models. Results Significant positive associations were found. Each one-unit increase in PM2.5, NO₂, and O₃ was associated with 0.3% (95% CI: 0.1–0.5%), 1.8% (1.2–2.4%), and 0.6% (0.3–0.9%) increases in overall incidence, respectively, at the population level. The exposure‒response relationships were nonlinear, with critical lag windows of 3–4 years for PM2.5 and 3 years for O₃. Stratified analyses revealed greater male susceptibility to PM2.5, whereas females were more vulnerable to NO₂ and O₃. High-middle-SDI regions had the highest PM2.5 risk, whereas low-middle-SDI regions were most affected by NO₂ and O₃. Adults aged ≥70 years face the highest risk, with females showing elevated susceptibility after age 60. Conclusion These ecological findings highlight the importance of considering air pollution in gastric cancer prevention frameworks, although the results must be validated by individual-level studies across diverse settings before causal inferences can be drawn.
- Open Access
- 6 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1753
Hypoxia Associated Integration of Epigenetic, Metabolic, and Immune Biomarkers in Blood and Urine for Early Colorectal Cancer Detection: A Multimarker Panel
Background: Detection of colorectal cancer (CRC) currently relies mainly on invasive procedures such as colonoscopy. In experimental models, tumor hypoxia induces epigenetic, metabolic, and immune changes via hypoxia-inducible factor (HIF) signaling. Building on these published insights, this study evaluated whether a panel of biomarkers previously associated with hypoxia-related processes, plasma methylated SEPT9 (mSEPT9), urinary N1, N12-diacetylspermine (DiAcSpm), and systemic inflammatory indices (NLR, PLR, and LMR)—could be combined into a non-invasive diagnostic panel and compared with standard serum tumor markers. This study focused solely on diagnostic performance; it did not directly assess tumor hypoxia or HIF expression in patients. This study was conducted in a clinical diagnostic setting (patients with confirmed CRC, polyps, or benign surgical conditions) and does not represent a population-based screening cohort. Limitations include the lack of an external validation cohort; all analyses were performed on a single dataset, and the reported performance metrics may be optimistic. Independent validation is required before clinical implementation. Methods: This prospective single-center study enrolled 382 participants: 142 with CRC, 62 with colorectal polyps, and 178 non-malignant controls. Plasma mSEPT9 was quantified by real-time PCR, urinary DiAcSpm by ELISA, and inflammatory indices from blood counts. Serum tumor markers (CEA, CA19-9, CA125, and AFP) were measured by immunoassay. Diagnostic accuracy was assessed using ROC analysis and multivariable logistic regression. Results: mSEPT9 (AUC 0.843) and DiAcSpm (AUC 0.831) demonstrated significantly higher diagnostic accuracy than CEA (AUC 0.660) and CA19-9 (AUC 0.649). A combined panel including mSEPT9, DiAcSpm, NLR, PLR, and LMR achieved an AUC of 0.947, with 85.9% sensitivity and 92.9% specificity. This panel also showed strong performance for early-stage CRC (AUC 0.905). Conclusions: A multimarker panel of biomarkers (mSEPT9, DiAcSpm, NLR, PLR, and LMR) provides a non-invasive diagnostic approach for CRC detection in a clinical case–control setting. Validation in asymptomatic screening populations is required before any screening claim can be made. These findings are associative; direct evidence that tumor hypoxia drives these biomarker changes was not obtained and requires future investigation.
- 6 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1753
Open AccessHypoxia Associated Integration of Epigenetic, Metabolic, and Immune Biomarkers in Blood and Urine for Early Colorectal Cancer Detection: A Multimarker Panel
Background: Detection of colorectal cancer (CRC) currently relies mainly on invasive procedures such as colonoscopy. In experimental models, tumor hypoxia induces epigenetic, metabolic, and immune changes via hypoxia-inducible factor (HIF) signaling. Building on these published insights, this study evaluated whether a panel of biomarkers previously associated with hypoxia-related processes, plasma methylated SEPT9 (mSEPT9), urinary N1, N12-diacetylspermine (DiAcSpm), and systemic inflammatory indices (NLR, PLR, and LMR)—could be combined into a non-invasive diagnostic panel and compared with standard serum tumor markers. This study focused solely on diagnostic performance; it did not directly assess tumor hypoxia or HIF expression in patients. This study was conducted in a clinical diagnostic setting (patients with confirmed CRC, polyps, or benign surgical conditions) and does not represent a population-based screening cohort. Limitations include the lack of an external validation cohort; all analyses were performed on a single dataset, and the reported performance metrics may be optimistic. Independent validation is required before clinical implementation. Methods: This prospective single-center study enrolled 382 participants: 142 with CRC, 62 with colorectal polyps, and 178 non-malignant controls. Plasma mSEPT9 was quantified by real-time PCR, urinary DiAcSpm by ELISA, and inflammatory indices from blood counts. Serum tumor markers (CEA, CA19-9, CA125, and AFP) were measured by immunoassay. Diagnostic accuracy was assessed using ROC analysis and multivariable logistic regression. Results: mSEPT9 (AUC 0.843) and DiAcSpm (AUC 0.831) demonstrated significantly higher diagnostic accuracy than CEA (AUC 0.660) and CA19-9 (AUC 0.649). A combined panel including mSEPT9, DiAcSpm, NLR, PLR, and LMR achieved an AUC of 0.947, with 85.9% sensitivity and 92.9% specificity. This panel also showed strong performance for early-stage CRC (AUC 0.905). Conclusions: A multimarker panel of biomarkers (mSEPT9, DiAcSpm, NLR, PLR, and LMR) provides a non-invasive diagnostic approach for CRC detection in a clinical case–control setting. Validation in asymptomatic screening populations is required before any screening claim can be made. These findings are associative; direct evidence that tumor hypoxia drives these biomarker changes was not obtained and requires future investigation.
- Open Access
- 1 June 2026
- Published by Frontiers Media SA in Frontiers in Aging
- Vol. 7, 1826382
Gut microbiota-epigenetic interactions in systemic aging: mechanistic drivers for endocrine and reproductive network remodeling and therapeutic modulation
Researchers now see aging as a process shaped by the interactions among metabolism, epigenetics, and hormones. Recent studies suggest that gut microbes play an important role in this system by making metabolites that can affect gene expression and chromatin structure. Still, it is not fully clear how gut microbes and the body influence each other as we age, since both are constantly changing. This review brings together current research on how metabolites from gut microbes—such as short-chain fatty acids, bile acids, tryptophan derivatives, and polyamines—affect the body’s epigenetic machinery through processes such as DNA methylation, histone modifications, and chromatin remodeling. We examine evidence from cell studies, animal experiments, and human research to assess the strength of the links and distinguish direct effects on chromatin from indirect metabolic or gene-expression changes. We focus especially on endocrine and reproductive organs, such as the hypothalamus, pancreas, liver, fat tissue, and cells that support the gonads, where signals from gut microbes overlap with hormonal control and metabolism. In these tissues, microbial metabolites influence key pathways related to inflammation, mitochondria, and nutrient sensing, but there is still little direct evidence in humans. The review also points out differences between lab models and what is observed in patients, highlighting the need for further work to apply these findings in real-world settings. Interactions between gut microbes and epigenetics form a two-way link between metabolism, immunity, and aging of the endocrine system. While more evidence shows that microbial metabolites can shape gene activity and epigenetic patterns, most of what we know comes from animal studies rather than direct tests in people. Moving forward, researchers will need to use broad, long-term studies that combine different types of data to figure out cause and effect and which tissues are involved. Understanding this system better could help create new biomarkers and treatments to influence aging by targeting the microbiome and its effects on epigenetics.
- 1 June 2026
- Published by Frontiers Media SA in Frontiers in Aging
- Vol. 7, 1826382
Open AccessGut microbiota-epigenetic interactions in systemic aging: mechanistic drivers for endocrine and reproductive network remodeling and therapeutic modulation
Researchers now see aging as a process shaped by the interactions among metabolism, epigenetics, and hormones. Recent studies suggest that gut microbes play an important role in this system by making metabolites that can affect gene expression and chromatin structure. Still, it is not fully clear how gut microbes and the body influence each other as we age, since both are constantly changing. This review brings together current research on how metabolites from gut microbes—such as short-chain fatty acids, bile acids, tryptophan derivatives, and polyamines—affect the body’s epigenetic machinery through processes such as DNA methylation, histone modifications, and chromatin remodeling. We examine evidence from cell studies, animal experiments, and human research to assess the strength of the links and distinguish direct effects on chromatin from indirect metabolic or gene-expression changes. We focus especially on endocrine and reproductive organs, such as the hypothalamus, pancreas, liver, fat tissue, and cells that support the gonads, where signals from gut microbes overlap with hormonal control and metabolism. In these tissues, microbial metabolites influence key pathways related to inflammation, mitochondria, and nutrient sensing, but there is still little direct evidence in humans. The review also points out differences between lab models and what is observed in patients, highlighting the need for further work to apply these findings in real-world settings. Interactions between gut microbes and epigenetics form a two-way link between metabolism, immunity, and aging of the endocrine system. While more evidence shows that microbial metabolites can shape gene activity and epigenetic patterns, most of what we know comes from animal studies rather than direct tests in people. Moving forward, researchers will need to use broad, long-term studies that combine different types of data to figure out cause and effect and which tissues are involved. Understanding this system better could help create new biomarkers and treatments to influence aging by targeting the microbiome and its effects on epigenetics.
- Open Access
- 30 April 2026
- Published by MDPI AG in Preprints.org
Hypoxia-Associated Integration of Epigenetic, Metabolic, and Immune Biomarkers in Blood and Urine for Early Colorectal Cancer Detection: A Multimarker Panel
Background: Early detection of colorectal cancer (CRC) still relies mainly on invasive screening. Tumor hypoxia induces epigenetic, metabolic, and immune changes via hypoxia-inducible factor (HIF) signaling in experimental models. Building on these insights, this study evaluated whether hypoxia pathway biomarkers—plasma methylated SEPT9 (mSEPT9), urinary N¹, N¹² diacetylspermine (DiAcSpm), and systemic inflammatory indices (NLR, PLR, LMR)—could be combined into a noninvasive diagnostic panel compared with standard serum tumor markers. The study focused solely on diagnostic performance; it did not directly assess tumor hypoxia or HIF expression in patients. Methods: This prospective single-center study enrolled 382 participants: 142 with CRC, 62 with colorectal polyps, and 178 non-malignant controls. Plasma mSEPT9 was quantified by real-time PCR, urinary DiAcSpm by ELISA, and inflammatory indices from blood counts. Serum tumor markers (CEA, CA19-9, CA125, AFP) were measured by immunoassay. Diagnostic accuracy was assessed using ROC analysis and multivariable modeling. Results: mSEPT9 (AUC 0.843) and DiAcSpm (AUC 0.831) demonstrated significantly higher diagnostic accuracy than CEA (AUC 0.660) and CA19-9 (AUC 0.649). A combined panel including mSEPT9, DiAcSpm, NLR, PLR, and LMR achieved an AUC of 0.947, with 85.9% sensitivity and 92.9% specificity. This panel also showed strong performance for early-stage CRC (AUC 0.905).” Conclusions: A multimarker panel of previously reported hypoxia-associated biomarkers (mSEPT9, DiAcSpm, NLR, PLR, and LMR) provides a scalable, noninvasive approach for CRC detection with high diagnostic accuracy. These findings are associative; direct evidence that tumor hypoxia drives these biomarker changes in patients was not obtained and requires future investigation.
- 30 April 2026
- Published by MDPI AG in Preprints.org
Open AccessHypoxia-Associated Integration of Epigenetic, Metabolic, and Immune Biomarkers in Blood and Urine for Early Colorectal Cancer Detection: A Multimarker Panel
Background: Early detection of colorectal cancer (CRC) still relies mainly on invasive screening. Tumor hypoxia induces epigenetic, metabolic, and immune changes via hypoxia-inducible factor (HIF) signaling in experimental models. Building on these insights, this study evaluated whether hypoxia pathway biomarkers—plasma methylated SEPT9 (mSEPT9), urinary N¹, N¹² diacetylspermine (DiAcSpm), and systemic inflammatory indices (NLR, PLR, LMR)—could be combined into a noninvasive diagnostic panel compared with standard serum tumor markers. The study focused solely on diagnostic performance; it did not directly assess tumor hypoxia or HIF expression in patients. Methods: This prospective single-center study enrolled 382 participants: 142 with CRC, 62 with colorectal polyps, and 178 non-malignant controls. Plasma mSEPT9 was quantified by real-time PCR, urinary DiAcSpm by ELISA, and inflammatory indices from blood counts. Serum tumor markers (CEA, CA19-9, CA125, AFP) were measured by immunoassay. Diagnostic accuracy was assessed using ROC analysis and multivariable modeling. Results: mSEPT9 (AUC 0.843) and DiAcSpm (AUC 0.831) demonstrated significantly higher diagnostic accuracy than CEA (AUC 0.660) and CA19-9 (AUC 0.649). A combined panel including mSEPT9, DiAcSpm, NLR, PLR, and LMR achieved an AUC of 0.947, with 85.9% sensitivity and 92.9% specificity. This panel also showed strong performance for early-stage CRC (AUC 0.905).” Conclusions: A multimarker panel of previously reported hypoxia-associated biomarkers (mSEPT9, DiAcSpm, NLR, PLR, and LMR) provides a scalable, noninvasive approach for CRC detection with high diagnostic accuracy. These findings are associative; direct evidence that tumor hypoxia drives these biomarker changes in patients was not obtained and requires future investigation.
- Open Access
- 23 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-14
Comprehensive characterization of the molecular feature of acetylation in colorectal cancer using integrated single-cell and bulk RNA sequencing
Colorectal cancer (CRC) remains a major global health burden with high mortality rates, underscoring the need for effective therapies. This study explores the acetylation characteristics in CRC using single-cell RNA sequencing (scRNA-seq) and weighted gene co-expression network analysis (WGCNA), assessing their relationship with prognosis and the immune microenvironment. We analyzed two scRNA-seq datasets from the GEO database to identify distinct cell subtypes. Acetylation activity scores were calculated using the ssGSEA method. A WGCNA was constructed to identify gene modules associated with acetylation. An acetylation-related prognostic signature (ARPS) was developed, and its clinical significance was evaluated through survival analysis and immune landscape characterization. Acetylation activity was significantly elevated in epithelial, endothelial, and stromal cells. Based on the results of scRNA-seq, WGCNA identified 169 acetylation-related genes. Intersection with 1,691 acetylation-related differentially expressed genes (DEGs) yielded 131 common genes. Combining clinical data with the expression profiles of these genes, we employed 101 machine learning algorithms to develop an ARPS that accurately predicts the prognosis of CRC patients. Low-risk patients showed increased infiltration of immune cells, enhanced immune function, and better responses to immunotherapy. These findings underscore the clinical significance of acetylation features in CRC prognosis and immune response, highlighting their potential as biomarkers and therapeutic targets.
- 23 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-14
Open AccessComprehensive characterization of the molecular feature of acetylation in colorectal cancer using integrated single-cell and bulk RNA sequencing
Colorectal cancer (CRC) remains a major global health burden with high mortality rates, underscoring the need for effective therapies. This study explores the acetylation characteristics in CRC using single-cell RNA sequencing (scRNA-seq) and weighted gene co-expression network analysis (WGCNA), assessing their relationship with prognosis and the immune microenvironment. We analyzed two scRNA-seq datasets from the GEO database to identify distinct cell subtypes. Acetylation activity scores were calculated using the ssGSEA method. A WGCNA was constructed to identify gene modules associated with acetylation. An acetylation-related prognostic signature (ARPS) was developed, and its clinical significance was evaluated through survival analysis and immune landscape characterization. Acetylation activity was significantly elevated in epithelial, endothelial, and stromal cells. Based on the results of scRNA-seq, WGCNA identified 169 acetylation-related genes. Intersection with 1,691 acetylation-related differentially expressed genes (DEGs) yielded 131 common genes. Combining clinical data with the expression profiles of these genes, we employed 101 machine learning algorithms to develop an ARPS that accurately predicts the prognosis of CRC patients. Low-risk patients showed increased infiltration of immune cells, enhanced immune function, and better responses to immunotherapy. These findings underscore the clinical significance of acetylation features in CRC prognosis and immune response, highlighting their potential as biomarkers and therapeutic targets.
- Open Access
- 15 December 2023
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (5)
Macrophages enhance cisplatin resistance in gastric cancer through the transfer of circTEX2
Cisplatin‐based chemotherapy is often used in advanced gastric cancer (GC) treatment, yet resistance to cisplatin may lead to treatment failure. Mechanisms underlying cisplatin resistance remain unclear. Recent evidence highlighted the role of macrophages in cancer chemoresistance. Macrophage‐derived exosomes were shown to facilitate intercellular communication. Here, we investigated the cisplatin resistance mechanism based on macrophage‐derived exosomes in gastric cancer. Cell growth and apoptosis detection experiments revealed that M2‐polarized macrophages increased the resistance of GC cells to cisplatin. qRT‐PCR, RNAase R assay, actinomycin D assay and cell nucleo‐cytoplasmic separation experiments confirmed the existence of circTEX2 in macrophage cytoplasm, with a higher expression level in M2 macrophages than that in M1 macrophages. Further experiments showed that circTEX2 acted as microRNA sponges for miR‐145 and regulated the expression of ATP Binding Cassette Subfamily C Member 1 (ABCC1). Inhibition of the circTEX2/miR‐145/ABCC1 axis blocked the cisplatin resistance of gastric cancer induced by M2 macrophages, as evidenced by in vitro and in vivo experiments. In conclusion, our research suggests that the exosomal transfer of M2 macrophage‐derived circTEX2 enhances cisplatin resistance in gastric cancer through miR‐145/ABCC1. Additionally, communication between macrophages and cancer cells via exosomes may be a promising therapeutic target for the treatment of cisplatin‐resistant gastric cancer.
- 15 December 2023
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (5)
Open AccessMacrophages enhance cisplatin resistance in gastric cancer through the transfer of circTEX2
Cisplatin‐based chemotherapy is often used in advanced gastric cancer (GC) treatment, yet resistance to cisplatin may lead to treatment failure. Mechanisms underlying cisplatin resistance remain unclear. Recent evidence highlighted the role of macrophages in cancer chemoresistance. Macrophage‐derived exosomes were shown to facilitate intercellular communication. Here, we investigated the cisplatin resistance mechanism based on macrophage‐derived exosomes in gastric cancer. Cell growth and apoptosis detection experiments revealed that M2‐polarized macrophages increased the resistance of GC cells to cisplatin. qRT‐PCR, RNAase R assay, actinomycin D assay and cell nucleo‐cytoplasmic separation experiments confirmed the existence of circTEX2 in macrophage cytoplasm, with a higher expression level in M2 macrophages than that in M1 macrophages. Further experiments showed that circTEX2 acted as microRNA sponges for miR‐145 and regulated the expression of ATP Binding Cassette Subfamily C Member 1 (ABCC1). Inhibition of the circTEX2/miR‐145/ABCC1 axis blocked the cisplatin resistance of gastric cancer induced by M2 macrophages, as evidenced by in vitro and in vivo experiments. In conclusion, our research suggests that the exosomal transfer of M2 macrophage‐derived circTEX2 enhances cisplatin resistance in gastric cancer through miR‐145/ABCC1. Additionally, communication between macrophages and cancer cells via exosomes may be a promising therapeutic target for the treatment of cisplatin‐resistant gastric cancer.